John is the president of Thread. He is an executive intrapreneur turned digital health entrepreneur. John’s career includes 17+ years leading global drug development and healthcare innovation. As President of THREAD, he leads the organization to enable our customers to launch, adopt and scale Virtual Visits + eCOA for their decentralized studies.
Named one of the Top 100 Influencers in Digital Health, John provides expertise and execution experience in digital health strategy, remote patient research, virtual clinical trials, Phase I - IV clinical research, patient reported outcomes, patient engagement and mobile health. He is also a regular keynote speaker at global industry events, guest lecturer at Duke University on digital health/innovation and a published author featured in various conferences, journals, articles and media outlets. Connect with John on LinkedIn and Twitter.
The truth is that the more study leaders utilize decentralized clinical trial approaches to expand access to eligible patients and introduce new efficiencies into studies, the more costs they can remove, thus reducing research costs overall.
By enabling a more hybrid approach to clinical trials with the added flexibility of telehealth, studies can improve patient-centricity, which will ultimately improve recruitment, engagement, and retention.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.